Biocon India to set up facilities for human insulin and biologicalsIllustrative image – not actual.

Biocon India has taken steps to set up facilities for manufacture of human insulin and biologicals with an investment of Rs.150 crore.

 

The facility for human insulin is estimated to cost Rs.50 crore and is expected to become operational by March 2003. A tie up has been concluded with Shantha Biotechnics for marketing human insulin.

 

The biologicals plant, costing Rs.100 crore, is likely to be commissioned by January 2004. The plant would manufacture mono-clonal anti-bodies, especially in the anti-cancer segment. Biocon also plans take up production of streptokinaze enzymes at this plant. The streptokinaze enzymes are used to break down blood clots especially in cardio-vascular surgeries. Clinigene of USA has been roped in for clinical trials.

← All latest storiesBack to top →